Table 2.
Significant clinical variables associated with TMPRSS1 and TMPRSS3 mRNA expression
| TMPRSS1 expressiona | TMPRSS3 expressiona | |||||
|---|---|---|---|---|---|---|
| Clinical variable | n (%) | P | Median / IQR | n (%) | P | Median / IQR |
| Tumor type | 0.002 | NS | ||||
| Benign | 16 (11.3) | 0.27 / 0.57 | 23 (12.1) | 0.98 / 0.56 | ||
| Malignant | 125 (88.7) | 0.96 / 2.10 | 167 (87.9) | 0.92 / 1.74 | ||
| Tumor grade | 0.000015 | 0.0002 | ||||
| I | 24 (19.5) | 0.000007b | 2.03 / 2.74 | 28 (17.3) | 0.016b | 1.76 / 2.80 |
| II | 51 (41.5) | NSc | 1.67 / 2.41 | 74 (45.7) | NSc | 1.29 / 2.03 |
| III | 48 (39.0) | 0.000004d | 0.55 / 0.88 | 60 (37.0) | 0.0001d | 0.55 / 0.84 |
| ER status | 0.000003 | 0.0027 | ||||
| Negative | 40 (32.5) | 0.45 / 0.84 | 50 (31.1) | 0.55 / 0.84 | ||
| Positive | 83 (67.5) | 1.67 / 2.44 | 111 (68.9) | 1.24 / 2.34 | ||
| PR status | 0.001 | 0.0076 | ||||
| Negative | 56 (45.5) | 0.59 / 1.39 | 70 (43.5) | 0.67 / 1.21 | ||
| Positive | 67 (54.5) | 1.53 / 2.57 | 91 (56.5) | 1.32 / 2.41 | ||
| HER2 status | 0.001 | 0.017 | ||||
| Negative | 99 (83.9) | 1.12 / 2.25 | 130 (84.4) | 1.08 / 2.46 | ||
| Positive | 19 (16.1) | 0.35 / 0.75 | 24 (15.6) | 0.58 / 0.89 | ||
| ER/PR/HER2 status | 0.001 | NS | ||||
| Triple-negative | 24 (20.3) | 0.49 / 0.98 | 29 (19.2) | 0.69 / 1.86 | ||
| Non-triple-negative | 94 (79.7) | 1.12 / 2.33 | 122 (80.8) | 1.09 / 1.81 | ||
IQR, Interquartile range; NS, Not significant
aMann-Whitney U test was used for subgroups of two variables and Kruskal-Wallis test for subgroups of several variables
bP value for comparing mRNA expression in benign tumors versus grade I tumors
cP value for comparing mRNA expression in grade I tumors versus grade II tumors
dP value for comparing mRNA expression in grade I tumors versus grade III tumors